Phaseline

Companies › BioNet-Asia

BioNet-Asia: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Vaccines.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Recombinant acellular pertussis (aP) vaccine (Pertagen®)
Recombinant acellular pertussis vaccine containing genetically detoxified pertussis toxin
–Phase 3Pertussis Vaccine–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06798831Recombinant acellular pertussis (aP) vaccine (Pertagen®)Phase 3Pertussis VaccineVaccinesApr 2025

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Liaoning Chengda Biotechnology Beijing Minhai Biotechnology Medigen Vaccine Biologics Sinovac (Dalian) Vaccine Technology Sinovac Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.